TRCT
NBIX icon

Tower Research Capital (TRC)’s Neurocrine Biosciences NBIX Stock Holding History

Tower Research Capital (TRC)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$536K Buy
4,070
+1,028
+34% +$136K 0.01% 871
2025
Q4 		$431K Sell
3,042
-2,256
-43% -$327K 0.01% 912
2025
Q3 		$744K Buy
5,298
+2,425
+84% +$329K 0.02% 638
2025
Q2 		$361K Sell
2,873
-3,550
-55% -$407K 0.01% 1262
2025
Q1 		$710K Sell
6,423
-4,157
-39% -$527K 0.02% 660
2024
Q4 		$1.44M Buy
10,580
+8,323
+369% +$1.03M 0.03% 467
2024
Q3 		$260K Sell
2,257
-416
-16% -$57K 0.01% 1373
2024
Q2 		$368K Sell
2,673
-3,617
-58% -$496K 0.01% 1590
2024
Q1 		$868K Sell
6,290
-7,863
-56% -$1.07M 0.02% 580
2023
Q4 		$1.86M Buy
14,153
+3,808
+37% +$438K 0.02% 535
2023
Q3 		$1.16M Sell
10,345
-1,658
-14% -$175K 0.04% 478
2023
Q2 		$1.13M Buy
12,003
+6,043
+101% +$590K 0.04% 440
2023
Q1 		$603K Buy
5,960
+3,106
+109% +$323K 0.02% 722
2022
Q4 		$341K Sell
2,854
-2,068
-42% -$242K 0.01% 934
2022
Q3 		$523K Sell
4,922
-10,275
-68% -$1.04M 0.01% 1103
2022
Q2 		$1.48M Buy
15,197
+4,280
+39% +$395K 0.03% 479
2022
Q1 		$1.02M Sell
10,917
-3,161
-22% -$268K 0.01% 777
2021
Q4 		$1.2M Buy
14,078
+7,846
+126% +$722K 0.02% 608
2021
Q3 		$598K Sell
6,232
-11,086
-64% -$1.05M 0.02% 866
2021
Q2 		$1.69M Buy
17,318
+3,498
+25% +$335K 0.04% 373
2021
Q1 		$1.34M Buy
13,820
+477
+4% +$50K 0.02% 627
2020
Q4 		$1.28M Buy
13,343
+10,388
+352% +$1M 0.04% 382
2020
Q3 		$284K Buy
2,955
+2,564
+656% +$297K ﹤0.01% 2228
2020
Q2 		$48K Buy
391
+321
+459% +$35.5K ﹤0.01% 3084
2020
Q1 		$6K Buy
+70
New +$6.85K ﹤0.01% 2234
2019
Q4 		– Sell
-392
Closed -$35K – 4094
2019
Q3 		$35K Sell
392
-203
-34% -$19K ﹤0.01% 2047
2019
Q2 		$51K Buy
595
+246
+70% +$20.2K ﹤0.01% 1563
2019
Q1 		$31K Buy
+349
New +$29.2K ﹤0.01% 2019
2018
Q4 		– Sell
-162
Closed -$20K – 4171
2018
Q3 		$20K Buy
162
+61
+60% +$6.92K ﹤0.01% 2344
2018
Q2 		$10K Sell
101
-3,502
-97% -$313K ﹤0.01% 2785
2018
Q1 		$299K Buy
3,603
+3,456
+2,351% +$292K 0.03% 710
2017
Q4 		$11K Buy
147
+107
+268% +$7.3K ﹤0.01% 2498
2017
Q3 		$2K Sell
40
-271
-87% -$14.3K ﹤0.01% 3574
2017
Q2 		$14K Buy
311
+204
+191% +$9.89K ﹤0.01% 1420
2017
Q1 		$5K Buy
107
+55
+106% +$2.36K ﹤0.01% 2211
2016
Q4 		$2K Sell
52
-189
-78% -$8.56K ﹤0.01% 3438
2016
Q3 		$12K Buy
+241
New +$12K ﹤0.01% 1940
2016
Q2 		– Sell
-1,083
Closed -$43K – 4781
2016
Q1 		$43K Sell
1,083
-60
-5% -$2.38K 0.01% 861
2015
Q4 		$65K Buy
1,143
+746
+188% +$37.9K 0.01% 438
2015
Q3 		$16K Sell
397
-2,251
-85% -$109K ﹤0.01% 1933
2015
Q2 		$126K Sell
2,648
-4
-0.2% -$170 0.01% 634
2015
Q1 		$105K Buy
2,652
+459
+21% +$16.4K 0.01% 846
2014
Q4 		$49K Buy
2,193
+1,102
+101% +$20.9K ﹤0.01% 1043
2014
Q3 		$17K Buy
+1,091
New +$16.3K ﹤0.01% 2434
2014
Q2 		– Sell
-618
Closed -$10K – 4425
2014
Q1 		$10K Buy
+618
New +$10.6K ﹤0.01% 2610
2013
Q4 		– Sell
-4,478
Closed -$51K – 4769
2013
Q3 		$51K Buy
4,478
+591
+15% +$8.12K 0.01% 1897
2013
Q2 		$52K Buy
+3,887
New +$47.8K ﹤0.01% 906

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tower Research Capital (TRC)'s NBIX Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Neurocrine Biosciences (NBIX) stake by 34% in Q1 2026, buying an estimated $136K and bringing the position to 4,070 shares worth $536K. The position accounts for 0.01% of the portfolio, ranked #871.

Tower Research Capital (TRC) first reported a position in NBIX in Q2 2013 and has held it in 47 quarters since. The position peaked at $1.86M in Q4 2023. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Tower Research Capital (TRC) held 4,070 shares of Neurocrine Biosciences worth $536K as of Q1 2026.
  • Tower Research Capital (TRC) bought 1,028 Neurocrine Biosciences shares in Q1 2026, an estimated $136K.
  • Neurocrine Biosciences made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #871 holding.
  • Tower Research Capital (TRC) first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 47 quarters since.
  • Tower Research Capital (TRC)'s Neurocrine Biosciences position peaked at $1.86M in Q4 2023.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.